The validity of a PID algorithm with insulin feedback with adaptive insulin limits, located on hybrid closed-loop pump 670G, Medtronic (pump plus continuous glucose monitoring Sensor G3), was probed in a six-month randomized controlled trial in adults with type 1 diabetes [64]: the TIR increased from 55% at baseline to 70% after 26 weeks and remaining unchanged at 55% in the control group. Here, INS is linked to type 1 diabetes mellitus.